Iuliana Iordan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iuliana Iordan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alina Mititelu
Hematology, Emergency University Hospital of Bucharest , “Carol Davila” University of Medicine and Pharmacy , Bucharest , Romania
3 shared publications Ana Maria Vlădăreanu
2 shared publications- Ana-Maria Vladareanu
Hematology, Emergency University Hospital of Bucharest , “Carol Davila” University of Medicine and Pharmacy , Bucharest , Romania
2 shared publications - Anca Nicolescu
Hematology , Emergency University Hospital of Bucharest , Bucharest , Romania
2 shared publications Andreea Neculcea
2 shared publicationsAndreea Spînu
2 shared publications
Latest Publications
- 30 July 2024
- Published by Societatea Romana de Hematologie in Documenta Haematologica - Revista Romana de Hematologie
- Vol. 2 (2) , 103-111
Cutaneous Complications after Autologous Stem Cell Transplantation
Autologous stem cell transplantation (ASCT) has become more prevalent for high-grade non-Hodgkin's lymphoma (NHL) over the past decade. ASCT serves as a salvage treatment for high-risk or relapsed patients, offering potential long-term remission. Cutaneous modifications post-ASCT can be classified as early (within 100 days) and late (after 100 days). Understanding these changes is crucial for timely diagnosis and management. Early modifications typically include transient erythema, hyperpigmentation, and acute dermatitis, often linked to the conditioning regimen. Late modifications, occurring months to years posttransplantation, can encompass chronic skin changes such as scleroderma-like features and persistent pigmentary alterations. Emerging evidence challenges the notion that ASCT is free of graft-versus-host disease (GVHD), with incidences of auto-GVHD reported. However, cutaneous GVHD post-ASCT, though uncommon, poses significant diagnostic challenges. Cutaneous GVHD manifestations range from mild eruptions to severe, systemic involvement. The role of skin biopsy in these cases is invaluable, providing histopathological confirmation and distinguishing GVHD from other dermatoses. Recognizing the early and late cutaneous modifications following ASCT is essential for clinicians. Despite the rarity of skin GVHD in ASCT, awareness and prompt biopsy can facilitate accurate diagnosis and appropriate management, improving patient outcomes.
- 30 July 2024
- Published by Societatea Romana de Hematologie in Documenta Haematologica - Revista Romana de Hematologie
- Vol. 2 (2) , 103-111
Cutaneous Complications after Autologous Stem Cell Transplantation
Autologous stem cell transplantation (ASCT) has become more prevalent for high-grade non-Hodgkin's lymphoma (NHL) over the past decade. ASCT serves as a salvage treatment for high-risk or relapsed patients, offering potential long-term remission. Cutaneous modifications post-ASCT can be classified as early (within 100 days) and late (after 100 days). Understanding these changes is crucial for timely diagnosis and management. Early modifications typically include transient erythema, hyperpigmentation, and acute dermatitis, often linked to the conditioning regimen. Late modifications, occurring months to years posttransplantation, can encompass chronic skin changes such as scleroderma-like features and persistent pigmentary alterations. Emerging evidence challenges the notion that ASCT is free of graft-versus-host disease (GVHD), with incidences of auto-GVHD reported. However, cutaneous GVHD post-ASCT, though uncommon, poses significant diagnostic challenges. Cutaneous GVHD manifestations range from mild eruptions to severe, systemic involvement. The role of skin biopsy in these cases is invaluable, providing histopathological confirmation and distinguishing GVHD from other dermatoses. Recognizing the early and late cutaneous modifications following ASCT is essential for clinicians. Despite the rarity of skin GVHD in ASCT, awareness and prompt biopsy can facilitate accurate diagnosis and appropriate management, improving patient outcomes.
- Open Access
- 20 October 2023
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (1) , 138-147
Frequency of thrombophilia-associated mutations and polymorphisms in pregnant women with a history of thrombosis or pregnancy complications
Objectives: To assess the frequency of multiple thrombophilia-associated mutations and polymorphisms in a selected population of high-risk pregnancies. Methods: Thrombophilia screening was performed for 1,500 pregnant women with prior pregnancy complications or thrombotic events. Nine thrombophilia-associated mutations or polymorphisms were screened: factor V Leiden, factor V H1299R, prothrombin G20210A, MTHFR C677T, MTHFR A1298C, factor XIII V34L, PAI-1 4G/5G polymorphisms, EPCR G4600A, EPCR C4678G. Results: Out of the 1,500 patients, 1,291 fulfilled the criteria for data interpretation. All patients had low-risk thrombophilia-associated genetic variants. Only 1.24 % of cases presented high-risk abnormalities (homozygous factor V Leiden/prothrombin G20210A, or both mutations in heterozygous form). Heterozygous factor V Leiden occurred in 10.38 % of cases, while only 5.81 % carried heterozygous prothrombin G20210A mutation. The frequency of prothrombin G20210A mutation was higher (10.37 %) in the subgroup associating factor V Leiden, than in the subgroup lacking it (5.36 %). Low-risk genetic variants occurred with a higher frequency: 23.78 % factor V H1299R, 57.32 % MTHFR C677T, 55.54 % MTHFR A1298C, 44.07 % factor XIII V34L, 73.20 % PAI-1 4G/5G polymorphisms, 69.64 % EPCR G4600A, and 69.63 % EPCR C4678G. Conclusions: All patients had at least one prothrombotic genetic mutation or variant. Our data highlight the need for thrombophilia screening, including low-risk genetic variants, in a high-risk population of pregnant women with a history of pregnancy complications or thrombotic events.
- 20 October 2023
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (1) , 138-147
Open AccessFrequency of thrombophilia-associated mutations and polymorphisms in pregnant women with a history of thrombosis or pregnancy complications
Objectives: To assess the frequency of multiple thrombophilia-associated mutations and polymorphisms in a selected population of high-risk pregnancies. Methods: Thrombophilia screening was performed for 1,500 pregnant women with prior pregnancy complications or thrombotic events. Nine thrombophilia-associated mutations or polymorphisms were screened: factor V Leiden, factor V H1299R, prothrombin G20210A, MTHFR C677T, MTHFR A1298C, factor XIII V34L, PAI-1 4G/5G polymorphisms, EPCR G4600A, EPCR C4678G. Results: Out of the 1,500 patients, 1,291 fulfilled the criteria for data interpretation. All patients had low-risk thrombophilia-associated genetic variants. Only 1.24 % of cases presented high-risk abnormalities (homozygous factor V Leiden/prothrombin G20210A, or both mutations in heterozygous form). Heterozygous factor V Leiden occurred in 10.38 % of cases, while only 5.81 % carried heterozygous prothrombin G20210A mutation. The frequency of prothrombin G20210A mutation was higher (10.37 %) in the subgroup associating factor V Leiden, than in the subgroup lacking it (5.36 %). Low-risk genetic variants occurred with a higher frequency: 23.78 % factor V H1299R, 57.32 % MTHFR C677T, 55.54 % MTHFR A1298C, 44.07 % factor XIII V34L, 73.20 % PAI-1 4G/5G polymorphisms, 69.64 % EPCR G4600A, and 69.63 % EPCR C4678G. Conclusions: All patients had at least one prothrombotic genetic mutation or variant. Our data highlight the need for thrombophilia screening, including low-risk genetic variants, in a high-risk population of pregnant women with a history of pregnancy complications or thrombotic events.
- Open Access
- 1 January 2023
- Published by MedicHub Media in Oncolog-Hematolog.ro
- Vol. 1 (62) , 26
Complicaţii mediate imunologic ale anticorpilor monoclonali folosiţi în oncohematologie
Monoclonal antibodies have emerged as effective treatments for a wide range of hematological and oncological disorders. Even though the majority of these medications have a superior tolerance and safety profile than traditional chemotherapy, an increasing number and variety of immune-mediated complications have been identified. There have been reports of both hematological and non-hematological side effects which can affect almost every organ. Therefore, clinicians must be aware of these adverse events since the early detection and the correct therapy are critical in reducing morbidity and mortality.
- 1 January 2023
- Published by MedicHub Media in Oncolog-Hematolog.ro
- Vol. 1 (62) , 26
Open AccessComplicaţii mediate imunologic ale anticorpilor monoclonali folosiţi în oncohematologie
Monoclonal antibodies have emerged as effective treatments for a wide range of hematological and oncological disorders. Even though the majority of these medications have a superior tolerance and safety profile than traditional chemotherapy, an increasing number and variety of immune-mediated complications have been identified. There have been reports of both hematological and non-hematological side effects which can affect almost every organ. Therefore, clinicians must be aware of these adverse events since the early detection and the correct therapy are critical in reducing morbidity and mortality.
- Open Access
- 1 January 2022
- Published by MedicHub Media in Oncolog-Hematolog.ro
- Vol. 2 (59) , 29
Trombocitopenia imună refractară – prezentare de caz
Immune thrombocytopenia is an autoimmune disorder that involves the platelet destruction in the spleen. Often, patients do not respond to conventional therapy. The management of refractory or relapsed immune thrombocytopenia poses a challenge for hematologist. We report the case of a 43-year-old patient in whom conventional treatment was not successful but who responded to TPO agonist eltrombopag.
- 1 January 2022
- Published by MedicHub Media in Oncolog-Hematolog.ro
- Vol. 2 (59) , 29
Open AccessTrombocitopenia imună refractară – prezentare de caz
Immune thrombocytopenia is an autoimmune disorder that involves the platelet destruction in the spleen. Often, patients do not respond to conventional therapy. The management of refractory or relapsed immune thrombocytopenia poses a challenge for hematologist. We report the case of a 43-year-old patient in whom conventional treatment was not successful but who responded to TPO agonist eltrombopag.
- Open Access
- 1 January 2022
- Published by MedicHub Media in Oncolog-Hematolog.ro
- Vol. 1 (58) , 46
Un caz rar de limfom Burkitt agresiv cu multiple infiltrate extranodale la un vârstnic
Burkitt lymphoma is one of the most aggressive non-Hodgkin lymphomas. The disease can be associated with extranodal involvement, especially in the structures of the neck and head, abdomen, kidneys and bone marrow. Breast involvement is rare. This type of lymphoma has an intrinsic propensity for central nervous system involvement. We report the case of an elderly patient diagnosed with Burkitt lymphoma with breast tumor and central nervous system infiltrates.
- 1 January 2022
- Published by MedicHub Media in Oncolog-Hematolog.ro
- Vol. 1 (58) , 46
Open AccessUn caz rar de limfom Burkitt agresiv cu multiple infiltrate extranodale la un vârstnic
Burkitt lymphoma is one of the most aggressive non-Hodgkin lymphomas. The disease can be associated with extranodal involvement, especially in the structures of the neck and head, abdomen, kidneys and bone marrow. Breast involvement is rare. This type of lymphoma has an intrinsic propensity for central nervous system involvement. We report the case of an elderly patient diagnosed with Burkitt lymphoma with breast tumor and central nervous system infiltrates.